{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T00:31:10Z","timestamp":1793579470011,"version":"4.5.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T00:00:00Z","timestamp":1763078400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-02992-2","type":"journal-article","created":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T16:19:43Z","timestamp":1763137183000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Favorable outcomes of SGLT2 inhibitor use in pacemaker recipients: a population-based study"],"prefix":"10.1186","volume":"24","author":[{"given":"Yuval","family":"Avidan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asaf","family":"Danon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Hadar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Aker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Yahav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oren","family":"Caspi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer","family":"Kassem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,14]]},"reference":[{"issue":"1","key":"2992_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2014-000177","volume":"1","author":"PJ Bradshaw","year":"2014","unstructured":"Bradshaw PJ, Stobie P, Knuiman MW, Briffa TG, Hobbs MST. Trends in the incidence and prevalence of cardiac pacemaker insertions in an ageing population. Open Heart. 2014;1(1):e000177.","journal-title":"Open Heart"},{"issue":"23","key":"2992_CR2","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1161\/01.CIR.0000072769.17295.B1","volume":"107","author":"MO Sweeney","year":"2003","unstructured":"Sweeney MO, Hellkamp AS, Ellenbogen KA, Greenspon AJ, Freedman RA, Lee KL, et al. Adverse effect of ventricular pacing on heart failure and atrial fibrillation among patients with normal baseline QRS duration in a clinical trial of pacemaker therapy for sinus node dysfunction. Circulation. 2003;107(23):2932\u20137.","journal-title":"Circulation"},{"issue":"35","key":"2992_CR3","doi-asserted-by":"publisher","first-page":"3427","DOI":"10.1093\/eurheartj\/ehab364","volume":"42","author":"M Glikson","year":"2021","unstructured":"Glikson M, Nielsen JC, Kronborg MB, Michowitz Y, Auricchio A, Barbash IM, et al. 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021;42(35):3427\u2013520.","journal-title":"Eur Heart J"},{"issue":"9","key":"2992_CR4","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1016\/j.jacc.2004.06.074","volume":"44","author":"M Nahlawi","year":"2004","unstructured":"Nahlawi M, Waligora M, Spies SM, Bonow RO, Kadish AH, Goldberger JJ. Left ventricular function during and after right ventricular pacing. J Am Coll Cardiol. 2004;44(9):1883\u20138.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2992_CR5","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/S0002-8703(05)80237-6","volume":"119","author":"PP Karpawich","year":"1990","unstructured":"Karpawich PP, Justice CD, Cavitt DL, Chang CH. Developmental sequelae of fixed-rate ventricular pacing in the immature canine heart: an electrophysiologic, hemodynamic, and histopathologic evaluation. Am Heart J. 1990;119(5):1077\u201383.","journal-title":"Am Heart J"},{"issue":"6","key":"2992_CR6","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0735-1097(00)00593-3","volume":"35","author":"JC Nielsen","year":"2000","unstructured":"Nielsen JC, B\u00f8ttcher M, Toftegaard Nielsen T, Pedersen AK, Andersen HR. Regional myocardial blood flow in patients with sick sinus syndrome randomized to long-term single chamber atrial or dual chamber pacing\u2014effect of pacing mode and rate. J Am Coll Cardiol. 2000;35(6):1453\u201361.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"2992_CR7","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1111\/j.1540-8159.1999.tb00631.x","volume":"22","author":"PP Karpawich","year":"1999","unstructured":"Karpawich PP, Rabah R, Haas JE. Altered cardiac histology following apical right ventricular pacing in patients with congenital atrioventricular block. Pacing Clin Electrophysiol. 1999;22(9):1372\u20137.","journal-title":"Pacing Clin Electrophysiol"},{"issue":"3","key":"2992_CR8","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s10840-015-0059-4","volume":"44","author":"M Schwerg","year":"2015","unstructured":"Schwerg M, Dreger H, Poller WC, Dust B, Melzer C. Efficacy of optimal medical therapy and cardiac resynchronization therapy upgrade in patients with pacemaker-induced cardiomyopathy. J Interv Card Electrophysiol. 2015;44(3):289\u201396.","journal-title":"J Interv Card Electrophysiol"},{"key":"2992_CR9","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.amjcard.2020.05.017","volume":"128","author":"O Dor","year":"2020","unstructured":"Dor O, Haim M, Barrett O, Novack V, Konstantino Y. Incidence and clinical outcomes of pacing induced cardiomyopathy in patients with normal left ventricular systolic function and atrioventricular block. Am J Cardiol. 2020;128:174\u201380.","journal-title":"Am J Cardiol"},{"issue":"10","key":"2992_CR10","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCEP.124.013070","volume":"17","author":"TA Boyle","year":"2024","unstructured":"Boyle TA, Pothineni NVK, Austin M, Shivamurthy P, Markman T, Guandalini G, et al. Incidence and predictors of pacing-induced right ventricular cardiomyopathy. Circ Arrhythm Electrophysiol. 2024;17(10):e013070.","journal-title":"Circ Arrhythm Electrophysiol"},{"issue":"12","key":"2992_CR11","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1016\/j.hrthm.2016.09.027","volume":"13","author":"EL Kiehl","year":"2016","unstructured":"Kiehl EL, Makki T, Kumar R, Gumber D, Kwon DH, Rickard JW, et al. Incidence and predictors of right ventricular pacing-induced cardiomyopathy in patients with complete atrioventricular block and preserved left ventricular systolic function. Heart Rhythm. 2016;13(12):2272\u20138.","journal-title":"Heart Rhythm"},{"issue":"44","key":"2992_CR12","doi-asserted-by":"publisher","first-page":"3641","DOI":"10.1093\/eurheartj\/ehz584","volume":"40","author":"B Tayal","year":"2019","unstructured":"Tayal B, Fruelund P, Sogaard P, Riahi S, Polcwiartek C, Atwater BD, et al. Incidence of heart failure after pacemaker implantation: a nationwide Danish registry-based follow-up study. Eur Heart J. 2019;40(44):3641\u20138.","journal-title":"Eur Heart J"},{"issue":"9","key":"2992_CR13","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1016\/j.hrthm.2014.05.040","volume":"11","author":"S Khurshid","year":"2014","unstructured":"Khurshid S, Epstein AE, Verdino RJ, Lin D, Goldberg LR, Marchlinski FE, et al. Incidence and predictors of right ventricular pacing-induced cardiomyopathy. Heart Rhythm. 2014;11(9):1619\u201325.","journal-title":"Heart Rhythm"},{"key":"2992_CR14","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2504118","author":"SS Kim","year":"2024","unstructured":"Kim SS, Park HW. New insights into pacing induced cardiomyopathy. Rev Cardiovasc Med. 2024. https:\/\/doi.org\/10.31083\/j.rcm2504118.","journal-title":"Rev Cardiovasc Med"},{"issue":"36","key":"2992_CR15","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"37","key":"2992_CR16","doi-asserted-by":"publisher","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","volume":"44","author":"TA McDonagh","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44(37):3627\u201339.","journal-title":"Eur Heart J"},{"issue":"39","key":"2992_CR17","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","volume":"44","author":"N Marx","year":"2023","unstructured":"Marx N, Federici M, Sch\u00fctt K, M\u00fcller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44(39):4043\u2013140.","journal-title":"Eur Heart J"},{"issue":"1","key":"2992_CR18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12933-022-01480-1","volume":"21","author":"S Chen","year":"2022","unstructured":"Chen S, Coronel R, Hollmann MW, Weber NC, Zuurbier CJ. Direct cardiac effects of SGLT2 inhibitors. Cardiovasc Diabetol. 2022;21(1):45.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2992_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12933-023-01970-w","volume":"22","author":"E Carluccio","year":"2023","unstructured":"Carluccio E, Biagioli P, Reboldi G, Mengoni A, Lauciello R, Zuchi C, et al. Left ventricular remodeling response to SGLT2 inhibitors in heart failure: an updated meta-analysis of randomized controlled studies. Cardiovasc Diabetol. 2023;22(1):235.","journal-title":"Cardiovasc Diabetol"},{"key":"2992_CR20","doi-asserted-by":"publisher","DOI":"10.15420\/cfr.2023.25","author":"CN Nilsson","year":"2024","unstructured":"Nilsson CN, Ersb\u00f8ll MK, Gustafsson F. Haemodynamic effects of Sodium-glucose cotransporter 2 inhibitor treatment in chronic heart failure patients. Card Fail Rev. 2024. https:\/\/doi.org\/10.15420\/cfr.2023.25.","journal-title":"Card Fail Rev"},{"issue":"5","key":"2992_CR21","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.echo.2024.10.009","volume":"38","author":"M Acquaro","year":"2025","unstructured":"Acquaro M, Scelsi L, Mascolo C, Pelosi C, Greco A, Turco A, et al. Dapagliflozin effects on left ventricular remodeling and filling pressures in heart failure with reduced ejection fraction. J Am Soc Echocardiogr. 2025;38(5):395\u2013403.","journal-title":"J Am Soc Echocardiogr"},{"issue":"21","key":"2992_CR22","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008.","journal-title":"N Engl J Med"},{"issue":"16","key":"2992_CR23","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","volume":"385","author":"SD Anker","year":"2021","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451\u201361.","journal-title":"N Engl J Med"},{"issue":"12","key":"2992_CR24","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","volume":"387","author":"SD Solomon","year":"2022","unstructured":"Solomon SD, McMurray JJV, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398.","journal-title":"N Engl J Med"},{"key":"2992_CR25","doi-asserted-by":"crossref","unstructured":"Cautela J, Alexandre J. SGLT2 inhibitors in cancer patients: a paradigm shift in cardio-oncology? Eur J Prev Cardiol 2025;","DOI":"10.1093\/eurjpc\/zwaf146"},{"issue":"6","key":"2992_CR26","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaccao.2024.08.001","volume":"6","author":"AW Bhatti","year":"2024","unstructured":"Bhatti AW, Patel R, Dani SS, Khadke S, Makwana B, Lessey C, et al. SGLT2i and primary prevention of cancer therapy-related cardiac dysfunction in patients with diabetes. JACC CardioOncol. 2024;6(6):863\u201375.","journal-title":"JACC CardioOncol"},{"issue":"10365","key":"2992_CR27","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"C Baigent","year":"2022","unstructured":"Baigent C, Emberson JonathanR, Haynes R, Herrington WG, Judge P, Landray MJ, et al. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788\u2013801.","journal-title":"Lancet"},{"issue":"11","key":"2992_CR28","doi-asserted-by":"publisher","first-page":"410","DOI":"10.4330\/wjc.v5.i11.410","volume":"5","author":"F Akerstr\u00f6m","year":"2013","unstructured":"Akerstr\u00f6m F. The importance of avoiding unnecessary right ventricular pacing in clinical practice. World J Cardiol. 2013;5(11):410.","journal-title":"World J Cardiol"},{"issue":"9","key":"2992_CR29","doi-asserted-by":"publisher","first-page":"e17","DOI":"10.1016\/j.hrthm.2023.03.1538","volume":"20","author":"MK Chung","year":"2023","unstructured":"Chung MK, Patton KK, Lau CP, Dal Forno ARJ, Al-Khatib SM, Arora V, et al. 2023 HRS\/APHRS\/LAHRS guideline on cardiac physiologic pacing for the avoidance and mitigation of heart failure. Heart Rhythm. 2023;20(9):e17-91.","journal-title":"Heart Rhythm"},{"issue":"10","key":"2992_CR30","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1016\/j.hrthm.2019.03.026","volume":"16","author":"P Vijayaraman","year":"2019","unstructured":"Vijayaraman P, Herweg B, Dandamudi G, Mittal S, Bhatt AG, Marcantoni L, et al. Outcomes of His-bundle pacing upgrade after long-term right ventricular pacing and\/or pacing-induced cardiomyopathy: insights into disease progression. Heart Rhythm. 2019;16(10):1554\u201361.","journal-title":"Heart Rhythm"},{"issue":"4","key":"2992_CR31","doi-asserted-by":"publisher","DOI":"10.3349\/ymj.2017.58.4.703","volume":"58","author":"HB Gwag","year":"2017","unstructured":"Gwag HB, Chun KJ, Hwang JK, Park KM, On YK, Kim JS, et al. Comparison of de novo versus upgrade cardiac resynchronization therapy; focused on the upgrade for pacing-induced cardiomyopathy. Yonsei Med J. 2017;58(4):703.","journal-title":"Yonsei Med J"},{"key":"2992_CR32","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.040415","author":"MS Agha","year":"2025","unstructured":"Agha MS, Schaich CL, Rikhi R, Hari K, Bodziock G, Bhave P. Effect of medical therapy on reducing the risk of pacing-induced cardiomyopathy. J Am Heart Assoc. 2025. https:\/\/doi.org\/10.1161\/JAHA.124.040415.","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"2992_CR33","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1002\/ehf2.14353","volume":"10","author":"AS Perry","year":"2023","unstructured":"Perry AS, Maggioni AP, Tavazzi L, Levy WC. Beta-blocker use and mortality among patients with systolic heart failure and pacemaker rhythm. ESC Heart Fail. 2023;10(3):1972\u20139.","journal-title":"ESC Heart Fail"},{"key":"2992_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2025.112452","volume":"228","author":"C Sardu","year":"2025","unstructured":"Sardu C, Marfella LV, Rinaldi L, Sasso FC, Cozzolino D, Nappo F, et al. Effects of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on CRT response and clinical outcomes in in type 2 diabetes mellitus patients receiving chronic anti-diabetic medications: a multicenter observational study. Diabetes Res Clin Pract. 2025;228:112452.","journal-title":"Diabetes Res Clin Pract"},{"key":"2992_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107759","volume":"216","author":"C Sardu","year":"2025","unstructured":"Sardu C, Trotta MC, Marfella LV, D\u2019Amico G, La Marca C, Mauro C, et al. Effects of SGLT2i therapy on cardiac electrophysiological properties and arrhythmias in diabetic patients with implantable cardiac defibrillator. Pharmacol Res. 2025;216:107759.","journal-title":"Pharmacol Res"},{"issue":"6","key":"2992_CR36","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.hrthm.2022.01.029","volume":"19","author":"YS Lin","year":"2022","unstructured":"Lin YS, Lip GYH, Ho WC, Shi CS, Lin MH, Kuo TY, et al. Statins to prevent pacing-induced cardiomyopathy: evidence from the bench applied to clinical studies. Heart Rhythm. 2022;19(6):960\u20138.","journal-title":"Heart Rhythm"},{"key":"2992_CR37","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.117.003564","author":"FM Merchant","year":"2017","unstructured":"Merchant FM, Hoskins MH, Musat DL, Prillinger JB, Roberts GJ, Nabutovsky Y, et al. Incidence and time course for developing heart failure with high-burden right ventricular pacing. Circ Cardiovasc Qual Outcomes. 2017. https:\/\/doi.org\/10.1161\/CIRCOUTCOMES.117.003564.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"issue":"3","key":"2992_CR38","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s10741-022-10256-4","volume":"28","author":"G Novo","year":"2022","unstructured":"Novo G, Guarino T, Di Lisi D, Biagioli P, Carluccio E. Effects of SGLT2 inhibitors on cardiac structure and function. Heart Fail Rev. 2022;28(3):697\u2013707.","journal-title":"Heart Fail Rev"},{"issue":"7","key":"2992_CR39","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A \u201cThrifty Substrate\u201d Hypothesis. Diabetes Care. 2016;39(7):1108\u201314.","journal-title":"Diabetes Care"},{"issue":"5","key":"2992_CR40","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s10741-021-10173-y","volume":"27","author":"A Del Franco","year":"2022","unstructured":"Del Franco A, Ambrosio G, Baroncelli L, Pizzorusso T, Barison A, Olivotto I, et al. Creatine deficiency and heart failure. Heart Fail Rev. 2022;27(5):1605\u201316.","journal-title":"Heart Fail Rev"},{"issue":"3","key":"2992_CR41","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.jacbts.2016.11.009","volume":"2","author":"AR Wende","year":"2017","unstructured":"Wende AR, Brahma MK, McGinnis GR, Young ME. Metabolic origins of heart failure. JACC Basic Transl Sci. 2017;2(3):297\u2013310.","journal-title":"JACC Basic Transl Sci"},{"issue":"15","key":"2992_CR42","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/j.jacc.2019.01.056","volume":"73","author":"CG Santos-Gallego","year":"2019","unstructured":"Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, Ishikawa K, Watanabe S, Picatoste B, et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol. 2019;73(15):1931\u201344.","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"2992_CR43","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1161\/CIRCULATIONAHA.122.060805","volume":"146","author":"CG Santos-Gallego","year":"2022","unstructured":"Santos-Gallego CG, Mayr M, Badimon J. SGLT2 inhibitors in heart failure: targeted metabolomics and energetic metabolism. Circulation. 2022;146(11):819\u201321.","journal-title":"Circulation"},{"issue":"5","key":"2992_CR44","first-page":"575","volume":"4","author":"RP Juni","year":"2019","unstructured":"Juni RP, Kuster DWD, Goebel M, Helmes M, Musters RJP, van der Velden J, et al. Cardiac microvascular endothelial enhancement of cardiomyocyte function is impaired by inflammation and restored by Empagliflozin. JACC: Basic to Translat Sci. 2019;4(5):575\u201391.","journal-title":"JACC: Basic to Translat Sci"},{"issue":"18","key":"2992_CR45","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","volume":"146","author":"M Packer","year":"2022","unstructured":"Packer M. Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis. Circulation. 2022;146(18):1383\u2013405.","journal-title":"Circulation"},{"issue":"4","key":"2992_CR46","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/cbf.3792","volume":"41","author":"H Yaribeygi","year":"2023","unstructured":"Yaribeygi H, Maleki M, Atkin SL, Jamialahmadi T, Sahebkar A. SGLT2 inhibitors and autophagy in diabetes. Cell Biochem Funct. 2023;41(4):392\u20138.","journal-title":"Cell Biochem Funct"},{"key":"2992_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177355","volume":"992","author":"S Endo","year":"2025","unstructured":"Endo S, Kanamori H, Yoshida A, Naruse G, Komura S, Minatoguchi S, et al. Sodium-glucose cotransporter 2 inhibitor empagliflozin enhances autophagy and reverses remodeling in hearts with large, old myocardial infarctions. Eur J Pharmacol. 2025;992:177355.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"2992_CR48","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.123.015298","volume":"16","author":"CG Santos-Gallego","year":"2023","unstructured":"Santos-Gallego CG, Requena-Ib\u00e1\u00f1ez JA, Picatoste B, Fardman B, Ishikawa K, Mazurek R, et al. Cardioprotective effect of Empagliflozin and circulating ketone bodies during acute myocardial infarction. Circ Cardiovasc Imaging. 2023;16(4):e015298.","journal-title":"Circ Cardiovasc Imaging"},{"issue":"1","key":"2992_CR49","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12933-025-02699-4","volume":"24","author":"N Salerno","year":"2025","unstructured":"Salerno N, Ielapi J, Cersosimo A, Leo I, Di Costanzo A, Armentaro G, et al. Early hemodynamic impact of SGLT2 inhibitors in overweight cardiometabolic heart failure: beyond fluid offloading to vascular adaptation\u2013 a preliminary report. Cardiovasc Diabetol. 2025;24(1):141.","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"2992_CR50","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1093\/ndt\/gfy407","volume":"34","author":"P Sarafidis","year":"2019","unstructured":"Sarafidis P, Ferro CJ, Morales E, Ortiz A, Malyszko J, Hojs R, et al. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrol Dial Transplant. 2019;34(2):208\u201330.","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"2992_CR51","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1161\/HYPERTENSIONAHA.121.17005","volume":"77","author":"P Sarafidis","year":"2021","unstructured":"Sarafidis P, Papadopoulos CE, Kamperidis V, Giannakoulas G, Doumas M. Cardiovascular protection with sodium-glucose cotransporter-2 inhibitors and mineralocorticoid receptor antagonists in chronic kidney disease. Hypertension. 2021;77(5):1442\u201355.","journal-title":"Hypertension"},{"key":"2992_CR52","doi-asserted-by":"publisher","DOI":"10.2174\/2772432816666210901111616","author":"C Gavaghan","year":"2022","unstructured":"Gavaghan C. Pacemaker induced cardiomyopathy: an overview of current literature. Curr Cardiol Rev. 2022. https:\/\/doi.org\/10.2174\/2772432816666210901111616.","journal-title":"Curr Cardiol Rev"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02992-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02992-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02992-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T17:03:22Z","timestamp":1763139802000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02992-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,14]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2992"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02992-2","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,14]]},"assertion":[{"value":"14 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethical Review Committee of Carmel Medical Center, Haifa (protocol Number 007\u201325-CMC). The requirement for individual patient consent was wavied due to the use of retrospective, de-identified data.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"433"}}